Harmony Biosciences Holdings, Inc. (HRMY) revenue
Harmony Biosciences Holdings, Inc. (HRMY) reported revenue of $868.45M in fiscal 2025 (the year ended December 31, 2025). That is 21.5% higher than the $714.73M of fiscal 2024. Figures as of 18 Nov 2026, 12:28 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Revenue, fiscal 2025
- $868.45M
- Change on fiscal 2024
- +21.5%
- Growth, 5 years
- +40.3% a year
- Highest on record
- $868.45Mfiscal 2025
- Lowest on record
- $6.00Mfiscal 2019
- Fiscal years on record
- 72019–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Harmony Biosciences Holdings, Inc. revenue, in more detail
Over the five fiscal years to 2025 revenue grew at a compound 40.3% a year. Across the 7 fiscal years on record (2019–2025), the highest was $868.45M in fiscal 2025 and the lowest $6.00M in fiscal 2019.
Revenue by fiscal year
Harmony Biosciences Holdings, Inc. revenue, year by year
| Fiscal year | Revenue | Change | Year ended |
|---|---|---|---|
| 2025 | $868.45M | 21.5% up | |
| 2024 | $714.73M | 22.8% up | |
| 2023 | $582.02M | 32.9% up | |
| 2022 | $437.86M | 43.4% up | |
| 2021 | $305.44M | 91.2% up | |
| 2020 | $159.74M | 2,564.6% up | |
| 2019 | $6.00M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.
How to read it
Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.
Harmony Biosciences Holdings, Inc., figure by figure
- Harmony Biosciences Holdings, Inc. market cap
- Harmony Biosciences Holdings, Inc. earnings
- Harmony Biosciences Holdings, Inc. earnings per share (EPS)
- Harmony Biosciences Holdings, Inc. P/E ratio
- Harmony Biosciences Holdings, Inc. P/S ratio
- Harmony Biosciences Holdings, Inc. P/B ratio
- Harmony Biosciences Holdings, Inc. free cash flow
- Harmony Biosciences Holdings, Inc. operating margin
- Harmony Biosciences Holdings, Inc. dividend
- Harmony Biosciences Holdings, Inc. shares outstanding
- Harmony Biosciences Holdings, Inc. total debt
- Harmony Biosciences Holdings, Inc. cash on hand
- Harmony Biosciences Holdings, Inc. total assets
- Harmony Biosciences Holdings, Inc. return on equity (ROE)
- Harmony Biosciences Holdings, Inc. return on invested capital (ROIC)
Harmony Biosciences Holdings, Inc. (HRMY) overview: price, valuation and scorecard
Harmony Biosciences Holdings, Inc. revenue: questions and answers
What is Harmony Biosciences Holdings, Inc.'s revenue?
Harmony Biosciences Holdings, Inc. (HRMY) reported revenue of $868.45M in fiscal 2025 (the year ended December 31, 2025). That is 21.5% higher than the $714.73M of fiscal 2024.
What is the growth rate of Harmony Biosciences Holdings, Inc.'s revenue?
Over the five fiscal years to 2025 revenue grew at a compound 40.3% a year.
What are the highest and lowest revenue figures on record for Harmony Biosciences Holdings, Inc.?
Across the 7 fiscal years on record (2019–2025), the highest was $868.45M in fiscal 2025 and the lowest $6.00M in fiscal 2019.
How is Harmony Biosciences Holdings, Inc.'s revenue calculated?
Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For Harmony Biosciences Holdings, Inc. it is on record here for 7 fiscal years, 2019 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: revenue
All stocks guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Harmony Biosciences Holdings, Inc. (HRMY) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/HRMY/revenue
Underlying data: the company's filings with the SEC and Yahoo Finance.